Abstract:A healthy host-microbiome relationship, crucial for intestinal homeostasis, is established early in postnatal life. Imbalance in the neonatal microbiome may lead to the development of chronic pathological conditions later in life. Dysbiosis of the gut microbiota is increasingly being linked to the etiology of both intestinal and systemic illnesses such as irritable bowel disease (IBD), cardiovascular diseases and diabetes, as well as kidney and neurological disorders. Gut dysbiosis also leads to the development of colorectal cancer (CRC). Despite substantial research, little is known about the interactions between microorganisms, their hosts, and their environments, or whether dysbiosis is a cause or consequence of disease. According to a recent hypothesis, bacterial species living in the mucus layer of the colon may determine whether cellular homeostasis is retained or inflammatory processes are elicited, either through direct interaction with intestinal epithelium or indirectly via bacterial metabolites. Recently, high throughput deep-sequencing technology has enabled the characterization of the microbiota in patients suffering from intestinal or extra-intestinal disorders, and a strong association between dysbiosis and disease development was found. However, specific disease drivers still need to be identified in most cases. Small compounds and metabolites produced by gut bacterial flora act as signaling molecules, such as neurotransmitters and neuropeptides that can profoundly influence host physiology. These metabolites play a crucial role in modulating gut-brain crosstalk. There is growing evidence that neurological disorders such as Alzheimer's disease, Parkinson’s and others, may originate or be exaggerated in response to microbial dysbiosis either directly or indirectly interfering with the drugs through metabolites. The present evidence on the role of the gut microbiota in disease development and drug metabolism is summarized in this review. Based on available studies, we can explore the potential of gut flora to alleviate disease progression.

Hepatic drug metabolism and gut microbiome

Human Gut Microbiota and Drug Metabolism

Interplays between drugs and the gut microbiome

Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches

The metabolic effect of gut microbiota on drugs

Interaction between drugs and the gut microbiome

Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids

Impact of commonly used drugs on the composition and metabolic function of the gut microbiota

Integrating the gut microbiome and pharmacology

Gut microbiome and inflammation in cardiovascular drug response: trends in therapeutic success and commercial focus

Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism

Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs

Mechanisms and Clinical Implications of Human Gut Microbiota-Drug Interactions in the Precision Medicine Era

Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects

The role of gut microbiota and drug interactions in the development of colorectal cancer

Dysbiosis: Gut feeling

Gut microbiota interactions with anti-diabetic medications and pathogenesis of type 2 diabetes mellitus

The Interplay between Gut Microbiota and Oral Medications and Its Impact on Advancing Precision Medicine

The gut microbiota: cause and cure of gut diseases

Gut microbiome: A possible common therapeutic target for treatment of atherosclerosis and cancer

A critical need for 'gut neutrality': mitigating adverse drug–microbiome interactions